StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.3
Power Rank trend -> Rising
07/08/2024 11:18:00 EST
Alnylam Pharmaceuticals Inc (ALNY)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, ALNY has been trading in a range between $247.00 and $149.30 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
ALNY is breaking above top of the recent 20 day range at $247.00 and appears that it could have some more upside. If it enters a yellow zone the trend may be faltering - consider exiting or taking profits. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Alnylam Pharmaceuticals Inc $ALNY entered a Green zone 19 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $229.39, a potential down side of -8.62% from the recent price of 251.03. The stock is trading 0.73% (potential upside) below its 52 week high of $252.87 and 76.82 % (potential downside) above its 52 week low of $141.97 - based on the recent price.
Company Summary
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
News
| What's Next For Alnylam Stock After A 60% Rise In A Week? Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial for its cardiovascular drug, Amvuttra. Source: Forbes Fri, 28 Jun 2024 07:00:00 -0400 Sentiment: Positive |
| Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints. Source: Zacks Investment Research Tue, 25 Jun 2024 10:00:20 -0400 Sentiment: Positive |
| Alnylam CEO on what is next for heart disease drug CNBC's Angelica Peebles and Yvonne Greenstreet, Alnylam CEO, joins 'Fast Money' to talk the companies latest heart condition drug data and what the path to approval looks like. Source: CNBC Television Mon, 24 Jun 2024 18:40:11 -0400 Sentiment: Positive |
| HELIOS-B Shines Bright And Gives Alnylam Pharmaceuticals Another Blockbuster HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and cardiovascular events, with positive results in secondary endpoints and a good safety profile. Results support the use of Amvuttra as monotherapy or in combination with stabilizers in people with ATTR-CM, potentially generating billions in incremental revenue for Alnylam. Source: Seeking Alpha Mon, 24 Jun 2024 11:37:31 -0400 Sentiment: Positive |
| Alnylam Stock Soars on Strong Results in Heart Drug Study Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday after the biopharma firm announced strong results from a late-stage study of its RNA interference drug for a rare heart condition. Source: Investopedia Mon, 24 Jun 2024 11:26:18 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 252.87 52 Week Low: 141.975 Beta: 0.37 50 Day MA: 167.8082 200 Day MA: 167.0703 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.548 Forward PE: 0 Trailing PE: 0